Sign In
Buy NBIX
$167.35
+2.24 (+1.36%)
At Close: Jun 04, 2026
90% of Pediatric Participants on CRENESSITY versus 21% on Placebo Achieved ≥1 Threshold for Androstenedione Reduction or Glucocorticoid Reduction Observed Rates of Select Reproductive Hormone Normal
GRFS or NBIX: Which Is the Better Value Stock Right Now?
12:46pm, Thursday, 15'th May 2025
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Grifols (GRFS) and Neurocrine Biosciences (NBIX). But which of these two stocks presents investors with th
Most Studies Meeting the Literature Review Criteria Found That a Higher Glucocorticoid Dose was Statistically Significantly Associated with Adverse Clinical Outcomes Findings Presented at the 2025 Int
- Data Consistent Across All Patient Subgroups, Including Demographic Subgroups, by Baseline Androstenedione Levels and by Baseline Glucocorticoid Dose - Findings to be Presented at the 2025 Joint Con
Neurocrine Biosciences to Present at Upcoming Investor Conferences in May
04:01pm, Tuesday, 06'th May 2025
SAN DIEGO , May 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in May. Chief Executive Officer Kyle Gano and Vice-President o
Neurocrine Biosciences' Ingrezza Q1 Sales Prove Resilient, Analysts Boost Price Target
01:24pm, Tuesday, 06'th May 2025
Neurocrine Biosciences Inc. NBIX stock is trading higher on Tuesday after the company reported better-than-expected first-quarter 2025 earnings.
Neurocrine Biosciences Surges On 'Surprising' Momentum For Its Newest Drug
11:24am, Tuesday, 06'th May 2025
Neurocrine Biosciences shares catapulted Tuesday on "surprising commercial momentum" for its newest drug, Crenessity.
2 Pharma Stocks Staging Big Post-Earnings Moves
10:43am, Tuesday, 06'th May 2025
Biopharmaceutical giants Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Neurocrine Biosciences Inc (NASDAQ:NBIX) are fresh out of the earnings confessional, with very different results.
New multimedia awareness campaign empowers people living with tardive dyskinesia to stand up to stigma and speak openly with their healthcare provider about symptoms and treatment SAN DIEGO , May 6,
Neurocrine Biosciences, Inc. (NBIX) Q1 2025 Earnings Call Transcript
08:33pm, Monday, 05'th May 2025
Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Q1 2025 Results Conference Call May 5, 2025 4:30 PM ET Company Participants Todd Tushla - Vice President of Investor Relations Kyle Gano - Chief Executive O
Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say
06:30pm, Monday, 05'th May 2025
Although the revenue and EPS for Neurocrine (NBIX) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Stre
Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates
06:10pm, Monday, 05'th May 2025
Neurocrine Biosciences (NBIX) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.42 per share a year ago.
Neurocrine Biosciences Reports First Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance
04:01pm, Monday, 05'th May 2025
INGREZZA® (valbenazine) First-Quarter 2025 Net Product Sales of $545 Million and Reaffirms 2025 Net Product Sales Guidance of $2.5 - $2.6 Billion CRENESSITYTM (crinecerfont) First-Quarter 2025 Net Pr
-- Majority of individuals polled reported tardive dyskinesia negatively impacts their day-to-day ability to function, including individuals living with mild or moderate uncontrolled movements1 SAN DI
Tokyo, Japan and Cambridge, UK, 1 May 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its partner Neurocrine Biosciences Inc. (“Neurocrine”) has i
